Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 175 EUR 3.8% Market Closed
Market Cap: 17B EUR
Have any thoughts about
Sartorius Stedim Biotech SA?
Write Note

Intrinsic Value

The intrinsic value of one DIM stock under the Base Case scenario is 159.09 EUR. Compared to the current market price of 175 EUR, Sartorius Stedim Biotech SA is Overvalued by 9%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

DIM Intrinsic Value
159.09 EUR
Overvaluation 9%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Sartorius Stedim Biotech SA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for DIM cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about DIM?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Sartorius Stedim Biotech SA

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Sartorius Stedim Biotech SA

Provide an overview of the primary business activities
of Sartorius Stedim Biotech SA.

What unique competitive advantages
does Sartorius Stedim Biotech SA hold over its rivals?

What risks and challenges
does Sartorius Stedim Biotech SA face in the near future?

Has there been any significant insider trading activity
in Sartorius Stedim Biotech SA recently?

Summarize the latest earnings call
of Sartorius Stedim Biotech SA.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Sartorius Stedim Biotech SA.

Provide P/S
for Sartorius Stedim Biotech SA.

Provide P/E
for Sartorius Stedim Biotech SA.

Provide P/OCF
for Sartorius Stedim Biotech SA.

Provide P/FCFE
for Sartorius Stedim Biotech SA.

Provide P/B
for Sartorius Stedim Biotech SA.

Provide EV/S
for Sartorius Stedim Biotech SA.

Provide EV/GP
for Sartorius Stedim Biotech SA.

Provide EV/EBITDA
for Sartorius Stedim Biotech SA.

Provide EV/EBIT
for Sartorius Stedim Biotech SA.

Provide EV/OCF
for Sartorius Stedim Biotech SA.

Provide EV/FCFF
for Sartorius Stedim Biotech SA.

Provide EV/IC
for Sartorius Stedim Biotech SA.

Show me price targets
for Sartorius Stedim Biotech SA made by professional analysts.

What are the Revenue projections
for Sartorius Stedim Biotech SA?

How accurate were the past Revenue estimates
for Sartorius Stedim Biotech SA?

What are the Net Income projections
for Sartorius Stedim Biotech SA?

How accurate were the past Net Income estimates
for Sartorius Stedim Biotech SA?

What are the EPS projections
for Sartorius Stedim Biotech SA?

How accurate were the past EPS estimates
for Sartorius Stedim Biotech SA?

What are the EBIT projections
for Sartorius Stedim Biotech SA?

How accurate were the past EBIT estimates
for Sartorius Stedim Biotech SA?

Compare the revenue forecasts
for Sartorius Stedim Biotech SA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Sartorius Stedim Biotech SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Sartorius Stedim Biotech SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Sartorius Stedim Biotech SA compared to its peers.

Compare the P/E ratios
of Sartorius Stedim Biotech SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Sartorius Stedim Biotech SA with its peers.

Analyze the financial leverage
of Sartorius Stedim Biotech SA compared to its main competitors.

Show all profitability ratios
for Sartorius Stedim Biotech SA.

Provide ROE
for Sartorius Stedim Biotech SA.

Provide ROA
for Sartorius Stedim Biotech SA.

Provide ROIC
for Sartorius Stedim Biotech SA.

Provide ROCE
for Sartorius Stedim Biotech SA.

Provide Gross Margin
for Sartorius Stedim Biotech SA.

Provide Operating Margin
for Sartorius Stedim Biotech SA.

Provide Net Margin
for Sartorius Stedim Biotech SA.

Provide FCF Margin
for Sartorius Stedim Biotech SA.

Show all solvency ratios
for Sartorius Stedim Biotech SA.

Provide D/E Ratio
for Sartorius Stedim Biotech SA.

Provide D/A Ratio
for Sartorius Stedim Biotech SA.

Provide Interest Coverage Ratio
for Sartorius Stedim Biotech SA.

Provide Altman Z-Score Ratio
for Sartorius Stedim Biotech SA.

Provide Quick Ratio
for Sartorius Stedim Biotech SA.

Provide Current Ratio
for Sartorius Stedim Biotech SA.

Provide Cash Ratio
for Sartorius Stedim Biotech SA.

What is the historical Revenue growth
over the last 5 years for Sartorius Stedim Biotech SA?

What is the historical Net Income growth
over the last 5 years for Sartorius Stedim Biotech SA?

What is the current Free Cash Flow
of Sartorius Stedim Biotech SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Sartorius Stedim Biotech SA.

Business Breakdown

Sartorius Stedim Biotech SA, a key player in the biopharmaceutical industry, has positioned itself at the forefront of innovation in bioprocessing and laboratory solutions. Established in the early 2000s through the merger of Sartorius AG's biotech division and Stedim S.A., the company’s mission centers on enabling the development and production of life-saving biologics. With a comprehensive portfolio that includes bioprocessing equipment, research services, and laboratory instruments, Sartorius caters to a vast array of customers, from small biotech firms to large pharmaceuticals, ensuring seamless workflows in drug development and manufacturing. By leveraging cutting-edge technologies and...

Read More
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Sartorius Stedim Biotech SA

Current Assets 1.7B
Cash & Short-Term Investments 475.3m
Receivables 363.3m
Other Current Assets 859m
Non-Current Assets 6.4B
Long-Term Investments 36.7m
PP&E 1.7B
Intangibles 4.6B
Other Non-Current Assets 61.4m
Current Liabilities 873.8m
Accounts Payable 203.2m
Accrued Liabilities 76.1m
Other Current Liabilities 594.5m
Non-Current Liabilities 3.3B
Long-Term Debt 2.8B
Other Non-Current Liabilities 540m
Efficiency

Earnings Waterfall
Sartorius Stedim Biotech SA

Revenue
2.7B EUR
Cost of Revenue
-1.6B EUR
Gross Profit
1.1B EUR
Operating Expenses
-752.4m EUR
Operating Income
396.4m EUR
Other Expenses
-227.2m EUR
Net Income
169.2m EUR

Free Cash Flow Analysis
Sartorius Stedim Biotech SA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In Q1 2024, the company displayed a mixed performance due to regional and segment variations. Order intake rose by around 10%, led by strong performances in the Americas, contrasting with weaker sales revenue, especially in China. Advanced Therapy Solutions showed promising growth, while equipment sales lagged. EBITDA margin stood robust at 28.6%, with continued efficiency improvements expected to sustain profitability. For the full year, they project mid- to high single-digit revenue growth and an EBITDA margin slightly above 30%, anticipating a stronger second half driven by consumables recovery and a rebound in equipment demand.

What is Earnings Call?
Fundamental Scores

DIM Profitability Score
Profitability Due Diligence

Sartorius Stedim Biotech SA's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
Positive Operating Income
Positive 3-Year Average ROIC
56/100
Profitability
Score

Sartorius Stedim Biotech SA's profitability score is 56/100. The higher the profitability score, the more profitable the company is.

DIM Solvency Score
Solvency Due Diligence

Sartorius Stedim Biotech SA's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
46/100
Solvency
Score

Sartorius Stedim Biotech SA's solvency score is 46/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

DIM Price Targets Summary
Sartorius Stedim Biotech SA

Wall Street analysts forecast DIM stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DIM is 219.96 EUR with a low forecast of 135.34 EUR and a high forecast of 325.5 EUR.

Lowest
Price Target
135.34 EUR
23% Downside
Average
Price Target
219.96 EUR
26% Upside
Highest
Price Target
325.5 EUR
86% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for DIM?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for DIM is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

DIM Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA

Country

France

Industry

Life Sciences Tools & Services

Market Cap

17B EUR

Dividend Yield

0.39%

Description

Sartorius Stedim Biotech SA provides equipment and services for the development, quality assurance, and production processes of the biopharmaceutical industry. The company is headquartered in Aubagne, Paca and currently employs 10,409 full-time employees. The firm covers the segments of biotechnology and mechatronics. Sartorius provides services which help customers to implement complex and quality-critical processes in biopharmaceutical production and laboratory environments in a time- and cost-efficient way. The Company’s customers are from the biotech, pharma and food industries, as well as from public research institutes and laboratories. Sartorius operates its own production facilities in Europe, Asia and America, and also has sales offices and local representatives in more than 110 countries. The firm operates through its subsidiaries, including Sartorius Stedim Austria GmbH, Sartorius Stedim Plastics GmbH, BioOutsource Ltd and Wave Biotech AG, among others.

Contact

PACA
Aubagne
Zone Industrielle les Paluds Avenue de Jouques, Bp 1051, Aubagne Cedex
+33442845600.0
www.sartorius.com

IPO

1994-10-20

Employees

10 409

Officers

CEO & DIrector
Dr. Rene Faber
CFO & Member of Executive Board
Mr. Rainer Lehmann
Head of Investor Relations
Ms. Petra Muller
Head of Corporate Communications & IR
Ms. Petra Kirchhoff
Head of Controlling BPS
Olivier Guitard

See Also

Discover More
What is the Intrinsic Value of one DIM stock?

The intrinsic value of one DIM stock under the Base Case scenario is 159.09 EUR.

Is DIM stock undervalued or overvalued?

Compared to the current market price of 175 EUR, Sartorius Stedim Biotech SA is Overvalued by 9%.

Back to Top